α-synuclein, LRRK2 and their interplay in Parkinson's disease

Future Neurology

Volumn 7, Issue 2, 2012, Pages 145-153

  Liu, Guoxiang ^a   Aliaga, Leonardo ^a   Cai, Huaibin ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

synuclein; 14 3 3; actin; autophagy; ER; Golgi apparatus; leucine rich repeat kinase 2; Lewy body; microtubule; mitochondria; Parkinson's disease; proteasome

Indexed keywords

ACTIN; ALPHA SYNUCLEIN; LEUCINE RICH REPEAT KINASE 2; PROTEASOME; PROTEIN 14 3 3; UBIQUITIN;

ACTIN FILAMENT; ALPHA SYNUCLEIN GENE; AMINO ACID SUBSTITUTION; AUTOPHAGY; CELL TRANSPORT; ENDOPLASMIC RETICULUM; GENE FUNCTION; GENE INTERACTION; GENETIC ASSOCIATION; GOLGI COMPLEX; HUMAN; LEUCINE RICH REPEAT KINASE 2 GENE; LEWY BODY; MICROTUBULE ASSEMBLY; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; MUTATOR GENE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN FUNCTION; REVIEW;

EID: 84863237380     PISSN: 14796708     EISSN: 17486971     Source Type: Journal    
DOI: 10.2217/fnl.12.2     Document Type: Review

References (62)

1. Morris AD. James Parkinson, born April 11, 1755. Lancet 268(6867), 761-763 (1955).
2. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28, 57-87 (2005). (Pubitemid 41098899)
3. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 373(9680), 2055-2066 (2009).
4. Jellinger KA. Formation and development of Lewy pathology: a critical update. J. Neurol. 256(Suppl. 3), 270-279 (2009).
5. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann. Neurol. 60(4), 389-398 (2006). (Pubitemid 44684974)
6. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276(5321), 2045-2047 (1997). (Pubitemid 27443610)
7. Morris AD. James Parkinson, born April 11, 1755. Lancet 268(6867), 761-763 (1955).
8. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28, 57-87 (2005). (Pubitemid 41098899)
9. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 373(9680), 2055-2066 (2009).
10. Jellinger KA. Formation and development of Lewy pathology: a critical update. J. Neurol. 256(Suppl. 3), 270-279 (2009).
11. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann. Neurol. 60(4), 389-398 (2006). (Pubitemid 44684974)
12. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276(5321), 2045-2047 (1997). (Pubitemid 27443610)
13. Kräger R, Kuhn W, Mäller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18(2), 106-108 (1998).
14. Zarranz JJ, Kuhn W, Mäller T, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55(2), 164-173 (2004). (Pubitemid 38166992)
15. Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364(9440), 1167-1169 (2004). (Pubitemid 39296604)
16. Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302(5646), 841 (2003). (Pubitemid 37339619)
17. Iwai A, Masliah E, Yoshimoto M, et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14(2), 467-475 (1995).
18. Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sädhof TC. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329(5999), 1663-1667 (2010).
19. Chandra S, Gallardo G, Fernndez-Chacan R, Schläter OM, Sädhof TC. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123(3), 383-396 (2005). (Pubitemid 41546670)
20. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20(9), 3214-3220 (2000). (Pubitemid 30263139)
21. Abeliovich A, Schmitz Y, Farias I, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25(1), 239-252 (2000). (Pubitemid 30316525)
22. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287(5456), 1265-1269 (2000). (Pubitemid 30112148)
23. Bartels T, Choi JG, Selkoe DJ. Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477(7362), 107-110 (2011).
24. McLean PJ, Kawamata H, Ribich S, Hyman BT. Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J. Biol. Chem. 275(12), 8812-8816 (2000). (Pubitemid 30180236)
25. Lee HJ, Choi C, Lee SJ. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277(1), 671-678 (2002). (Pubitemid 34952106)
26. Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273(16), 9443-9449 (1998). (Pubitemid 28183026)
27. Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH. Lipid rafts mediate the synaptic localization of alpha-synuclein. J. Neurosci. 24(30), 6715-6723 (2004). (Pubitemid 38993891)
28. Simons K, Toomre D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1(1), 31-39 (2000).
29. Fujita Y, Ohama E, Takatama M, Al-Sarraj S, Okamoto K. Fragmentation of Golgi apparatus of nigral neurons with alpha-synuclein-positive inclusions in patients with Parkinson's disease. Acta Neuropathol. 112(3), 261-265 (2006). (Pubitemid 44275881)
30. Martin LJ, Pan Y, Price AC, et al. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26(1), 41-50 (2006). (Pubitemid 43089519)
31. Meredith GE, Totterdell S, Petroske E, Santa Cruz K, Callison RC Jr, Lau YS. Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res. 956(1), 156-165 (2002). (Pubitemid 35335568)
32. Cooper AA, Gitler AD, Cashikar A, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313(5785), 324-328 (2006). (Pubitemid 44480951)
33. Madine J, Doig AJ, Middleton DA. A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers. Biochemistry 45(18), 5783-5792 (2006).
34. Varkey J, Isas JM, Mizuno N, et al. Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins. J. Biol. Chem. 285(42), 32486-32493 (2010).
35. Gai WP, Yuan HX, Li XQ, Power JT, Blumbergs PC, Jensen PH. In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Exp. Neurol. 166(2), 324-333 (2000).
36. Lavedan C. The synuclein family. Genome Res. 8(9), 871-880 (1998). (Pubitemid 28495441)
37. Greten-Harrison B, Polydoro M, Morimoto- Tomita M, et al. Alphabetagamma-synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc. Natl Acad. Sci. USA 107(45), 19573-19578 (2010).
38. Chandra S, Fornai F, Kwon HB, et al. Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc. Natl Acad. Sci. USA 101(41), 14966-14971 (2004). (Pubitemid 39410782)
39. Kirik D, Rosenblad C, Burger C, et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22(7), 2780-2791 (2002). (Pubitemid 37465827)
40. Tan EK, Jankovic J. Genetic testing in Parkinson disease: promises and pitfalls. Arch. Neurol. 63(9), 1232-1237 (2006). (Pubitemid 44379821)
41. Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat. Rev. Neurosci. 11(12), 791-797 (2010).
42. Yue Z, Lachenmayer ML. Genetic LRRK2 models of Parkinson's disease: dissecting the pathogenic pathway and exploring clinical applications. Mov. Disord. 26(8), 1386-1397 (2011).
43. Tong Y, Yamaguchi H, Giaime E, et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc. Natl Acad. Sci. USA 107(21), 9879-9884 (2010).
44. Johnson SJ, Wade-Martins R. A BACwards glance at neurodegeneration: molecular insights into disease from LRRK2, SNCA and MAPT BAC-transgenic mice. Biochem. Soc. Trans. 39(4), 862-867 (2011).
45. Parisiadou L, Cai H. LRRK2 function on actin and microtubule dynamics in Parkinson disease. Commun. Integr. Biol. 3(5), 396-400 (2010).
46. Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281(40), 29739-29752 (2006). (Pubitemid 44536983)
47. Herzig MC, Kolly C, Persohn E, et al. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum. Mol. Genet. 20(21), 4209-4223 (2011).
48. Melrose HL, Dachsel JC, Behrouz B, et al. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol. Dis. 40(3), 503-517 (2010).
49. Horton AC, Ehlers MD. Secretory trafficking in neuronal dendrites. Nat. Cell Biol. 6(7), 585-591 (2004). (Pubitemid 38960915)
50. Lippincott-Schwartz J, Donaldson JG, Schweizer A, et al. Microtubule-dependent retrograde transport of proteins into the ER in the presence of brefeldin A suggests an ER recycling pathway. Cell 60(5), 821-836 (1990).
51. Winslow AR, Chen CW, Corrochano S, et al. Alpha-synuclein impairs macroautophagy: implications for Parkinson's disease. J. Cell Biol. 190(6), 1023-1037 (2010).
52. Bove J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2(3), 484-494 (2005). (Pubitemid 41444882)
53. Biskup S, Moore DJ, Celsi F, et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 60(5), 557-569 (2006). (Pubitemid 44871798)
54. Mortiboys H, Johansen KK, Aasly JO, Bandmann O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 75(22), 2017-2020 (2010).
55. Nandi D, Tahiliani P, Kumar A, Chandu D. The ubiquitin-proteasome system. J. Biosci. 31(1), 137-155 (2006).
56. Wang L, Xie C, Greggio E, et al. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J. Neurosci. 28(13), 3384-3391 (2008). (Pubitemid 351469333)
57. Tanaka Y, Engelender S, Igarashi S, et al. Inducible expression of mutant a-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10, 919-926 (2001). (Pubitemid 32401408)
58. Rubinsztein DC, Rubinsztein DC, DiFiglia M, et al. Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy 1(1), 11-22 (2005).
59. Plowey ED, Chu CT. Synaptic dysfunction in genetic models of Parkinson's disease: a role for autophagy? Neurobiol. Dis. 43(1), 60-67 (2011).
60. Xilouri M, Stefanis L. Autophagic pathways in Parkinson disease and related disorders. Expert Rev. Mol. Med. 13, e8 (2011).
61. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305(5688), 1292-1295 (2004). (Pubitemid 39129234)
62. Bjorklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci. 30(5), 194-202 (2007). (Pubitemid 46654237)